Quantinno Capital Management LP Boosts Holdings in Qiagen (NYSE:QGEN)

Quantinno Capital Management LP increased its stake in shares of Qiagen (NYSE:QGEN - Free Report) by 45.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 114,774 shares of the company's stock after purchasing an additional 36,067 shares during the period. Quantinno Capital Management LP owned approximately 0.05% of Qiagen worth $5,114,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in QGEN. Groupama Asset Managment lifted its stake in Qiagen by 8,074.0% during the fourth quarter. Groupama Asset Managment now owns 31,817,740 shares of the company's stock worth $1,416,844,000 after purchasing an additional 32,216,761 shares in the last quarter. Norges Bank purchased a new stake in shares of Qiagen in the 4th quarter valued at $181,529,000. Massachusetts Financial Services Co. MA lifted its stake in Qiagen by 9.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 25,319,332 shares of the company's stock worth $1,127,470,000 after acquiring an additional 2,202,040 shares in the last quarter. Caisse Des Depots ET Consignations purchased a new position in Qiagen during the 4th quarter valued at about $53,991,000. Finally, Barclays PLC grew its position in Qiagen by 170.6% in the 3rd quarter. Barclays PLC now owns 1,849,004 shares of the company's stock valued at $84,259,000 after acquiring an additional 1,165,594 shares in the last quarter. Institutional investors and hedge funds own 70.00% of the company's stock.

Wall Street Analyst Weigh In

QGEN has been the topic of several research reports. Redburn Atlantic cut shares of Qiagen from a "buy" rating to a "neutral" rating in a research report on Friday, April 4th. UBS Group reduced their target price on shares of Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a report on Friday, February 7th. StockNews.com raised shares of Qiagen from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 15th. Robert W. Baird boosted their price target on shares of Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a research note on Monday, April 21st. Finally, Baird R W cut Qiagen from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 19th. Seven investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $48.42.

Qiagen Stock Down 1.1%

Shares of Qiagen stock traded down $0.46 during trading on Wednesday, hitting $42.24. 1,718,495 shares of the stock were exchanged, compared to its average volume of 1,148,215. The stock has a market cap of $9.39 billion, a price-to-earnings ratio of 117.63, a price-to-earnings-growth ratio of 2.39 and a beta of 0.67. The firm's 50-day moving average price is $41.11 and its 200 day moving average price is $41.83. Qiagen has a 12-month low of $37.63 and a 12-month high of $49.30. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.61 and a quick ratio of 3.09.

Qiagen (NYSE:QGEN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share for the quarter, beating analysts' consensus estimates of $0.50 by $0.05. The company had revenue of $483.46 million for the quarter, compared to analysts' expectations of $465.66 million. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. Qiagen's quarterly revenue was up 5.2% on a year-over-year basis. During the same period last year, the firm earned $0.44 earnings per share. As a group, analysts forecast that Qiagen will post 2.26 earnings per share for the current fiscal year.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.